ACE and COVID-19: Both the CV and systemic ACE/ACE2 ratio could be crucial in the evolution of COVID-19 individuals, favoring either the cardiotoxic ACE/Ang-II/AT1R axis or the cardioprotective ACE2/Ang-(1–7)/MasR pathway [75].